Altimmune's weight loss drug minimizes muscle loss, study says
Only 25% of weight loss by participants in a clinical trial of Altimmune’s Pemvidutide came from a loss of lean mass
Stay updated with breaking news from Altimmune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Only 25% of weight loss by participants in a clinical trial of Altimmune’s Pemvidutide came from a loss of lean mass
Altimmune, Inc. (NASDAQ:ALT – Get Free Report) traded up 5.3% on Thursday . The company traded as high as $9.38 and last traded at $9.36. 660,352 shares changed hands during trading, a decline of 89% from the average session volume of 5,935,036 shares. The stock had previously closed at $8.89. Analyst Ratings Changes A number […]
The results are similar to the effects of diet and exercise, the company said.
Connective Portfolio Management LLC acquired a new stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) in the fourth quarter, Holdings Channel reports. The firm acquired 16,000 shares of the company’s stock, valued at approximately $180,000. Several other hedge funds have also recently modified their holdings of ALT. FNY Investment Advisers LLC purchased a […]
Connective Portfolio Management LLC bought a new stake in Altimmune, Inc. (NASDAQ:ALT – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 16,000 shares of the company’s stock, valued at approximately $180,000. Other hedge funds and other institutional investors also recently […]